biostudies-literatureTaya MCancer Prevention Research Institute of Texas Recruitment of Established Investigators AwardMayo Clinic SPORE in Ovarian Cancer Developmental Research Program, Pilot Study AwardNational Cancer InstituteNCI NIH HHSThe University of Chicago Women's BoardThe University of Chicago Comprehensive Cancer CenterThe University of Chicago Women’s Board2017 Conquer Cancer Foundation/ASCO Young Investigator Awarde4https://www.ebi.ac.uk/biostudies/studies/S-EPMC11790989biostudies-literatureUnknown36(1)<h4>Objective</h4>In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapy-induced OvCa cell death in association with transcriptional upregulation of genes encoding anti-apoptotic proteins. A recent randomized phase II study demonstrated improvement in progression-free survival (PFS) for heavily pre-treated OvCa patients randomized to receive therapy with a selective GR modulator (SGRM) plus chemotherapy compared to chemotherapy alone. We hypothesized that SGRM therapy would improve carboplatin response in OvCa patient-derived xenograft (PDX).<h4>Methods</h4>Six high-grade serous (HGS) OvCa PDX models expressing GR mRNA (<i>NR3C1</i>) and protein were treated with chemotherapy +/- Journal of gynecologic oncologyInvestigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.PMC11790989P30 CA 14599NIH1R21CA223426P50 CA136393RR19003715P50CA136393-09P30 CA142543P30 CA014599R21 CA223426Taya MOberg ALHeinzen EPChen HHou XFleming GFVeneris JTMaurer MJLarson MCKazi NConzen SDLastra RWeroha SJfalseInvestigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.<h4>Objective</h4>In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapy-induced OvCa cell death in association with transcriptional upregulation of genes encoding anti-apoptotic proteins. A recent randomized phase II study demonstrated improvement in progression-free survival (PFS) for heavily pre-treated OvCa patients randomized to receive therapy with a selective GR modulator (SGRM) plus chemotherapy compared to chemotherapy alone. We hypothesized that SGRM therapy would improve carboplatin response in OvCa patient-derived xenograft (PDX).<h4>Methods</h4>Six high-grade serous (HGS) OvCa PDX models expressing GR mRNA (<i>NR3C1</i>) and protein were treated with chemotherapy +/- 2025-01-01T00:00:00Z2025 Jan2026-04-14T03:26:49.684Z2025-04-19T16:22:33.915ZS-EPMC117909893890964010.3802/jgo.2025.36.e4